

Evonik Financials - New Segment Structure (from April 1, 2025)

Custom Solutions
Advanced Technologies

P. 2
P. 3

As of Q1 2025 (published May 12, 2025)

in € million	2019	2020	2021	2022	2023	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
Sales	4,611	4,483	5,357	6,568	5,608	1,392	1,472	1,465	1,408	5,737	1,426
<i>Sales Additives</i>	3,127	2,965	3,588	4,523	3,747	975	1,017	981	935	3,908	973
<i>Sales Health & Care</i>	1,484	1,518	1,768	2,045	1,861	417	455	484	473	1,829	453
Adjusted EBITDA	972	942	1,086	1,162	852	231	281	287	179	978	256
<i>Margin (%)</i>	21.1%	21.0%	20.3%	17.7%	15.2%	16.6%	19.1%	19.6%	12.7%	17.0%	18.0%
EBIT						155	205	223	-25	558	
Adjusted EBIT						156	205	210	92	663	
Capital expenditures						49	59	71	132	311	
Capital employed (annual average)										6,644	
ROCE (%)										10.0%	

2019-2023 as well as Q1 2025 figures pro-forma (unaudited)

in € million	2019	2020	2021	2022	2023	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
Sales	5,063	4,967	5,827	7,092	5,983	1,517	1,533	1,535	1,504	6,089	1,601
<i>Sales Organics</i>	1,618	1,469	1,681	1,868	1,742	409	441	408	407	1,665	426
<i>Sales Inorganics</i>	2,007	2,024	2,357	3,031	2,491	625	641	615	608	2,490	621
<i>Sales Animal Nutrition</i>	1,438	1,474	1,789	2,193	1,750	483	450	512	489	1,934	554
Adjusted EBITDA	1,080	1,047	1,233	1,207	752	275	267	296	185	1,023	291
Margin (%)	21.3%	21.1%	21.2%	17.0%	12.6%	18.1%	17.4%	19.3%	12.3%	16.8%	18.2%
EBIT						158	157	205	-3	517	
Adjusted EBIT						159	157	186	62	565	
Capital expenditures						80	66	77	143	367	
Capital employed (annual average)										6,565	
ROCE (%)										8.6%	

2019-2023 as well as Q1 2025 figures pro-forma (unaudited)